Loading...
•
Mar 31, 2025
Atara Q1 2025 Earnings Report
Atara Biotherapeutics announced its first quarter 2025 financial results and operational progress.
Key Takeaways
Atara Biotherapeutics reported a significant increase in total revenues to $98.1 million for Q1 2025, up from $27.4 million in Q1 2024, primarily due to revenue recognized from the completion of performance obligations under its Pierre Fabre agreement. The company also reported a net income of $38.0 million, a substantial improvement from a net loss in the prior year period. Operating expenses decreased slightly year-over-year, and the company secured additional financing to extend its cash runway into Q1 2026.
Total revenues for Q1 2025 were $98.1 million, a significant increase from $27.4 million in Q1 2024.
The company reported a net income of $38.0 million for Q1 2025, compared to a net loss of $31.8 million in Q1 2024.
Atara secured $16 million in gross proceeds from an underwriting agreement, extending its cash runway through Q1 2026.
Atara transitioned all tab-cel manufacturing costs and responsibilities to Pierre Fabre Laboratories in Q1 2025.
Revenue by Segment
Forward Guidance
Atara expects to significantly reduce operating expenses in 2025, with a projected 65% year-over-year decrease, and anticipates its current funding, including recent proceeds, will support operations into the first quarter of 2026.
Positive Outlook
- Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025.
- The company's current cash, cash equivalents, and short-term investments, combined with the $16 million gross proceeds from the May 2025 offering, are expected to fund planned operations into the first quarter of 2026.
- Atara plans to resume enrollment in the Phase 3 ALLELE clinical study for EBV+ PTLD and the Phase 2 label-expansion multi-cohort clinical study.
- Atara remains eligible for significant milestone payments from Pierre Fabre Laboratories upon FDA approval of EBVALLOTM BLA and related commercial sales.
- The company is in active discussions on accelerating the transfer of all remaining operational activities related to tab-cel to Pierre Fabre, except BLA sponsorship, which is expected to be completed by June 2025.
Challenges Ahead
- Atara has paused development of its CAR T programs (ATA3219 and ATA3431), with wind-down activities anticipated to be completed in Q2 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...